Extending the Benefits of Targeting HER2 in Breast Cancer | Dana-Farber Cancer Institute
Вставка
- Опубліковано 8 вер 2024
- Nancy Lin, MD, and Paolo Tarantino, MD, discuss the outcomes of a recent study on HER2-low metastatic breast cancer from the ASCO 2022 Annual Meeting. They explain how the antibody-drug conjugate (ADC) trastuzumab deruxtecan (Enhertu) is now being used to treat HER2-low breast cancers.
This is an excellent presentation, even with its audio glitches. Finding detailed content on cancer is difficult on UA-cam. Thanks for being the exception.
Thank you
I am her+
Same 💖
Me three. I've been her2 + metastatic going on 6 and 1/2 years
Me 4
the quality of the video is really poor--very blurry